Navigation Links
Reduction in Antidepressant Leads to Suicidal Risks

Regulatory warnings regarding the risk of suicidal thoughts and behaviors appear to be associated with reductions in the number of antidepressant medication prescriptions among children and adolescents covered by Tennessees expanded Medicaid program.

Antidepressant medications are frequently used to treat depression among children and teens, but in 2003 data emerged regarding an increased risk of suicidal thinking and behavior among young patients taking these drugs, according to background information in the article.

In December 2003, the Committee on Safety of Medicines [the U.K. drug regulatory agency] declared the risk-benefit profile of all selective serotonin reuptake inhibitor (SSRI) antidepressants (as well as venlafaxine hydrochloride and mirtazapine), with the exception of fluoxetine, to be unfavorable for the treatment of major depressive disorders in children and adolescents, the authors write.

Shortly thereafter in 2004, the Food and Drug Administration convened a Psychopharmacology Advisory Committee meeting in February, issued a public health advisory in March, and in October required black box warning labels for all antidepressants (including fluoxetine) highlighting the potential increase in suicidal thinking and behavior in children and adolescents.

The warning recommended more intense therapeutic monitoring to mitigate these risks but did not suggest avoiding the pediatric use of antidepressants.

Benji T. Kurian, M.D., M.P.H., and colleagues at Vanderbilt University School of Medicine, Nashville, Tenn., examined monthly antidepressant prescription data among patients age 2 to 17 years covered by the TennCare expanded Medicare program. The study included the 45 months from Jan. 1, 2002, through Sept. 30, 2005, 12 months following the FDA black box warning, the authors write.

The study months were divided into two periods. The period before the regulatory warnings incl uded the 24 months from Jan. 1, 2002, through Dec. 31, 2003, and that after the regulatory warnings included the 21 months from Jan. 1, 2004, through Sept. 30, 2005. An average of 405,000 children and teens qualified for the study each month.

During the period before the regulatory warnings, there was little change from month to month in the rate of new antidepressant prescriptions, with an average of 23 per 10,000 patients. By the end of the studya total of 21 months after the U.K. warningsthis proportion had decreased by 33 percent to an average of 15 per 10,000 per month.

The decrease was most pronounced for SSRIs (except for fluoxetine) and another type of antidepressant linked to suicidal thoughts and behaviors, selective norepinephrine reuptake inhibitors.

New users of fluoxetine, the only antidepressant approved by the FDA for the treatment of depression in children and adolescents, increased by 60 percent. However, there was no evidence of an increase in discontinuations of therapy with antidepressant or other psychotropic drugs, which suggests that the primary effect of the warnings was to alter the decision to treat a newly presenting patient, the authors write.

Previous studies have shown that the use of antidepressants among TennCare patients is similar to that of children and adolescents in the entire United States, suggesting that a similar decrease may have occurred in other populations.

Because there is so much uncertainly regarding the pediatric use of antidepressants, the implications of these changes are unclear, the authors note. Thus, while it is now evident that regulatory interventions can alter patterns of practice, whether this is desirable is uncertain, they conclude. There is an urgent need for better data on the efficacy and safety of antidepressants to guide pediatric practice.


'"/>




Related medicine news :

1. Reduction in melanoma death rate
2. A Reduction In Calories Found To Yield More Benefits
3. Weight Reduction Surgery Also Treats Metabolic Syndrome
4. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
5. A Change In Lifestyle Can Help In Weight Reduction
6. Fat isnt all that bad: Reduction no predecessor of reduced disease
7. MP’s Ask for Reduction of VAT on Condoms, Essential Health Ite
8. Drugs plus Awareness Would Facilitate Reduction of HIV Infection
9. Heart Disease Risk Halved By Minimal Cholesterol Reduction
10. Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery
11. After Weight Reduction People Opt For Special Plastic Surgery to Tone Their Body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try using ... the health benefits of integrating clay into a daily diet are numerous, as clay ... speaker, Perry A~ has since dedicated her life to learning about the benefits of ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... greater than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth ... ”It is time to make a change in public health,” states Carole Baggerly, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Intarcia Therapeutics, Inc. today announced the appointment of ... created role of Vice President, Head of Global Medical ... of leadership experience at leading pharmaceutical, biotechnology, and health ... Most recently Dr. Yee served as VP, Head of ... Officer at AstraZeneca, where he led medical affairs across ...
(Date:2/8/2016)... BASEL , Switzerland and PALO ALTO, Calif. ... leader in biological and chemical manufacturing, and Kodiak Sciences ... for the treatment of retinal disease, announced today agreements ... the agreement, Lonza will manufacture material at multiple sites, ... --> --> Retinal ...
(Date:2/8/2016)... 2016 /PRNewswire/--  Cell Applications, Inc. and Cyfuse ... are now available in North America ... bioprinting approach called the "Kenzan Method." Utilizing Cyfuse ... state-of-the-art robotic system that fabricates 3D tissue from ... bio-printing model that makes scaffold-free tissue available immediately ...
Breaking Medicine Technology: